7 completed, 2 active not recruiting, 2 terminated. 8 Phase 1, 6 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Terminated 2, Active not recruiting 1 |
| Phase 2 | 6 | Completed 4, Active not recruiting 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow volagidemab: new trials by email Literature Review of volagidemab trials Research Report on volagidemab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes Sotagliflozin, Volagidemab - Type 1 Diabetes | Phase 1 / Phase 2 | Active not recruiting | University of California, San Diego | 24 | 2024-09-09 | 2026-06-15 |
| Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab Volagidemab - Type 1 Diabetes Mellitus | Phase 1 | Completed | REMD Biotherapeutics, Inc. | 24 | 2024-02-15 | 2025-06-03 |
| Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM REMD-477, Placebo Subcutaneous injection - Type 2 Diabetes, Glucose Tolerance Impaired | Early Phase 1 | Completed | The University of Texas Health Science Center at San Antonio | 4 | 2021-11-10 | 2024-08-09 |
| Effects of GRA in Patients With Type 1 REMD-477, Placebo - Type 1 Diabetes | Phase 2 | Active not recruiting | University of California, San Diego | 30 | 2021-07-31 | 2025-06-10 |
| Combination GRA and SGLT-2i Treatment in Type 1 Diabetes Dapagliflozin 10 MG [Farxiga], REMD-477, Placebo - Type 1 Diabetes | Phase 1 / Phase 2 | Completed | University of California, San Diego | 12 | 2021-02-22 | 2023-01-23 |
| Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477) REMD-477 - Hyperglycemia Drug Induced | Phase 1 | Terminated | Duke University | 1 | 2020-11-13 | 2022-11-08 |
| A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib REMD-477 - Hyperglycemia Drug Induced | Phase 1 | Terminated | Duke University | 1 | 2020-04-07 | 2021-06-11 |
| Metabolic Pathways of GRA in Patients With Type 1 Diabetes REMD-477 - Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Completed | University of California, San Diego | 4 | 2019-07-01 | 2022-07-15 |
| Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus REMD-477, Placebo Comparator - Type1 Diabetes Mellitus | Phase 2 | Completed | REMD Biotherapeutics, Inc. | 154 | 2017-09-19 | 2023-05-25 |
| Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus REMD-477, Placebo Comparator - Type 1 Diabetes Mellitus, Diabetes | Phase 1 | Completed | REMD Biotherapeutics, Inc. | 21 | 2016-03-01 | 2017-02-07 |
| Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus REMD-477 - Type 2 Diabetes Mellitus, Diabetes | Phase 1 / Phase 2 | Completed | REMD Biotherapeutics, Inc. | 75 | 2015-09-01 | 2018-04-10 |
Diabetes Mellitus, Type 1 (6) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (2) · Hyperglycemia (2) · Breast Neoplasms (1) · Glucose Intolerance (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Insulin Resistance (1) · Lymphoma (1)
REMD Biotherapeutics, Inc. (4) · University of California, San Diego (4) · Duke University (2) · The University of Texas Health Science Center at San Antonio (1)
United States (11)
Ralph DeFronzo, MD (1) · Susan Dent, MD (1) · Zung Thai, MD (1)